Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytoDyn Inc.
Report date January 10, 2019 · Filed January 10, 2019
Section 16 reporting ended · disclosed 2019-01-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2019-05-29 | Direct | 0 |
Reported balance
After 2019-01-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-10 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2024-05-29 | Direct | 100,000 |
Reported balance
After 2019-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-10 · Grant · Acquired 100,000 · Balance 100,000 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2019-06-01 | Direct | 0 |
Reported balance
After 2019-01-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2024-06-01 | Direct | 50,000 |
Reported balance
After 2019-01-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-10 · Grant · Acquired 50,000 · Balance 50,000 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions.
F2: Such options were fully vested and exercisable as of the date of the reported transactions.
GILEAD SCIENCES, INC.
Report date May 08, 2007 · Filed May 15, 2007
Section 16 reporting ended · disclosed 2007-05-15. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,897 | $65.74 | $256,188.78 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 19 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $65.73 | $6,573.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 18 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,897 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,800 | $65.72 | $184,016.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 17 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,997 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $65.71 | $26,284.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 16 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,797 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,100 | $65.70 | $466,470.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 15 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,197 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,100 | $65.69 | $729,159.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 14 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,297 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,900 | $65.68 | $715,912.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 13 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,397 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,500 | $65.65 | $229,775.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 12 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,297 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,300 | $65.64 | $216,612.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 11 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,797 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,200 | $65.63 | $144,386.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 10 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,097 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 700 | $65.62 | $45,934.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 9 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,297 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $65.61 | $6,561.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 8 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,997 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,800 | $65.60 | $314,880.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 7 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,097 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $65.59 | $39,354.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 6 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,897 Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $31.12 | $155,600.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 5 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 9,000 | $32.88 | $295,875.00 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 4 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,000 | $14.80 | $236,750.40 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 3 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,997 | $14.16 | $155,676.83 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 2 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2003 Filed Aug 22, 2003 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,500 | $34.33 | $360,412.50 |
DisclosureSEC source: 0001179110-03-006211 · edgar.xml · nonDerivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,287 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · derivative · entry 17 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,685 Underlying: Common Stock · 15,287 shares Expires 2009-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.16 | $0.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · derivative · entry 16 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,992 Underlying: Common Stock · 10,000 shares Expires 2010-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,028 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · derivative · entry 15 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,028 shares Expires 2005-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,356 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · derivative · entry 14 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,356 shares Expires 2006-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 5,713 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · derivative · entry 13 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,315 Underlying: Common Stock · 5,713 shares Expires 2003-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,356 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · derivative · entry 12 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,356 shares Expires 2006-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 26,440 | $62.43 | $1,650,649.20 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 11 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $62.64 | $31,320.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 10 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,440 Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 24,500 | $62.66 | $1,535,170.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 9 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,940 Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $62.67 | $12,534.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 8 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,440 Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,100 | $62.68 | $68,948.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 7 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,640 Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,500 | $63.08 | $94,620.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 6 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,740 Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $63.09 | $31,545.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 5 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,240 Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $14.16 | $141,563.00 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 4 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 21,000 | $17.08 | $358,642.20 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 3 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 22,712 | $6.81 | $154,661.91 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 2 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2003 Filed Aug 13, 2003 19:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,028 | $8.50 | $8,739.75 |
DisclosureSEC source: 0001179110-03-005522 · edgar.xml · nonDerivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2003 Filed Aug 7, 2003 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 39,466 | $0.00 Strike: $69.99 | $0.00 |
DisclosureSEC source: 0001179110-03-005143 · edgar.xml · derivative · entry 2 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,466 Underlying: Common Stock · 39,466 shares Expires 2013-07-30 F2 · derivative.exercise_date: 8,000 shares will vest on July 30, 2004, the first anniversary date of the grant. The balance vests quarterly thereafter until fully vested on July 30, 2008. Read SEC document |
| July 30, 2003 Filed Aug 7, 2003 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 534 | $0.00 Strike: $69.99 | $0.00 |
DisclosureSEC source: 0001179110-03-005143 · edgar.xml · derivative · entry 1 CARACCIOLO ANTHONY · CIK 0001258929 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534 Underlying: Common Stock · 534 shares Expires 2013-07-30 F1 · derivative.exercise_date: 534 shares will vest quarterly beginning on January 30, 2008 until fully vested on July 30, 2008. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.